Postinflammatory hyperpigmentation
Postinflammatory hyperpigmentation er en kutan tilstand karakteriseret ved øget pigment i huden efter betændelse i huden. Postinflammatory hyperpigmentation kan være forårsaget af langvarig soleksponering, betændelse eller andre hudskader, inklusive dem, der er relateret til acne. Mennesker med mørkere hudtoner er normalt mere tilbøjelige til hyperpigmentering med overskydende soleksponering.
☆ I 2022 Stiftung Warentest-resultaterne fra Tyskland var forbrugernes tilfredshed med ModelDerm kun lidt lavere end med betalte telemedicinske konsultationer.
References
Postinflammatory hyperpigmentation (PIH) er et hyppigt hudproblem, der opstår efter hudbetændelse eller skade. Det har en tendens til at vare længe og er værre hos mennesker med mørkere hudtoner (Fitzpatrick skin types III–VI) . Selvom det ofte bliver bedre af sig selv, kan dette tage et stykke tid, så der er ofte behov for behandling i længere tid. At kombinere forskellige behandlinger fungerer bedst.
Postinflammatory hyperpigmentation (PIH) is a common acquired cutaneous disorder occurring after skin inflammation or injury. It is chronic and is more common and severe in darker-skinned individuals (Fitzpatrick skin types III–VI). While the condition typically improves spontaneously, this process can take months to years, necessitating prolonged treatment. Combination therapy is the most effective.
Postinflammatory hyperpigmentation (PIH) is a common acquired cutaneous disorder occurring after skin inflammation or injury. It is chronic and is more common and severe in darker-skinned individuals (Fitzpatrick skin types III–VI). While the condition typically improves spontaneously, this process can take months to years, necessitating prolonged treatment. Combination therapy is the most effective.
Postinflammatory hyperpigmentation er en almindelig følgetilstand af hudbetændelse. Det har en tendens til at påvirke mørkere personer mere alvorligt og hyppigere. Undersøgelser viser, at problemer som postinflammatory hyperpigmentation er blandt hovedårsagerne til, at mennesker med mørkere hudtoner søger dermatologisk behandling. Tidlig behandling er afgørende for at løse postinflammatory hyperpigmentation og starter normalt med at håndtere den indledende betændelsestilstand. Den første behandlingslinje involverer typisk brug af topiske midler, der lysner huden sammen med solcreme til beskyttelse. Disse midler, som hydroquinone, azelaic acid, kojic acid, arbutin, licorice extracts , kan effektivt reducere overdreven pigmentering. Derudover bruges retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, soy også som depigmenterende midler, hvor nye behandlinger dukker op. Mens topiske behandlinger normalt er effektive til hyperpigmentering på overfladeniveau, kan procedurer (laser, chemical peel) være nødvendige for genstridige tilfælde. Det er vigtigt at være forsigtig med disse behandlinger for at undgå irritation og forværring af postinflammatory hyperpigmentation.
Postinflammatory hyperpigmentation is a common sequelae of inflammatory dermatoses that tends to affect darker skinned patients with greater frequency and severity. Epidemiological studies show that dyschromias, including postinflammatory hyperpigmentation, are among the most common reasons darker racial/ethnic groups seek the care of a dermatologist. The treatment of postinflammatory hyperpigmentation should be started early to help hasten its resolution and begins with management of the initial inflammatory condition. First-line therapy typically consists of topical depigmenting agents in addition to photoprotection including a sunscreen. Topical tyrosinase inhibitors, such as hydroquinone, azelaic acid, kojic acid, arbutin, and certain licorice extracts, can effectively lighten areas of hypermelanosis. Other depigmenting agents include retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, and soy with a number of emerging therapies on the horizon. Topical therapy is typically effective for epidermal postinflammatory hyperpigmentation; however, certain procedures, such as chemical peeling and laser therapy, may help treat recalcitrant hyperpigmentation. It is also important to use caution with all of the above treatments to prevent irritation and worsening of postinflammatory hyperpigmentation.
Postinflammatory hyperpigmentation is a common sequelae of inflammatory dermatoses that tends to affect darker skinned patients with greater frequency and severity. Epidemiological studies show that dyschromias, including postinflammatory hyperpigmentation, are among the most common reasons darker racial/ethnic groups seek the care of a dermatologist. The treatment of postinflammatory hyperpigmentation should be started early to help hasten its resolution and begins with management of the initial inflammatory condition. First-line therapy typically consists of topical depigmenting agents in addition to photoprotection including a sunscreen. Topical tyrosinase inhibitors, such as hydroquinone, azelaic acid, kojic acid, arbutin, and certain licorice extracts, can effectively lighten areas of hypermelanosis. Other depigmenting agents include retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, and soy with a number of emerging therapies on the horizon. Topical therapy is typically effective for epidermal postinflammatory hyperpigmentation; however, certain procedures, such as chemical peeling and laser therapy, may help treat recalcitrant hyperpigmentation. It is also important to use caution with all of the above treatments to prevent irritation and worsening of postinflammatory hyperpigmentation.
